



**CÔNG TY CỔ PHẦN
DUỐC PHẨM TRUNG ƯƠNG CPC1
CENTRAL PHARMACEUTICAL CPC1.JSC**

SOCIALIST REPUBLIC OF VIETNAM
Independence – Freedom – Happiness

Số/No.: 552 /CPC1-TCKT

Hanoi, 31 March 2025

V/v: Explanation of profit after tax in 2024 changing by 10% or more compared to 2023 and differing by 5% or more compared to accumulated profit after tax in the Quarter 4/2024 Financial Statements

To: - State Securities Commission of Vietnam
- Hanoi Stock Exchange

Pursuant to the Ministry of Finance's Circular 96/2020/TT-BTC, dated 16 November 2020, of guidance on information disclosure on the stock market.

Pursuant to the Financial Statements dated 31 December 2024 and 31 December 2023 of Central Pharmaceutical CPC1.JSC (the Company) audited by Ernst & Young Vietnam Limited, the Company would like to explain some of the following matters:

1. Profit after tax in the reporting period has a difference before and after auditing of 5% or more.

Accumulated profit after tax in Quarter 4/2024 is 132.98 billion VND, decreasing by 19.22 billion VND, equivalent to a decrease of 14.45% compared to the Profit after tax in the audited 2024 Financial Statements:

ASSETS	2024 audited) (VND)	Accumulated Quarter 4/2024 (VND)	Difference	
			Amount (VND)	Proportion
(1)	(2)	(3)	(4)=(2)-(3)	(5)=(4)/(3)
Profit after tax	113.758.603.232	132.975.841.659	(19.217.238.427)	(14,45%)

Reason: Due to adjustments of the data, the cost of goods sold and some expense items increased, so the profit after tax decreased.

2. Profit after tax in the 2024 Income Statement changed by 10% or more compared to the same period in the previous year:

ASSETS	2024 (VND)	2023 Restated) (VND)	Difference	
			Amount (VND)	Proportion
(1)	(2)	(3)	(4)=(2)-(3)	(5)=(4)/(3)
Profit after tax	113.758.603.232	102.952.579.256	10.806.023.976	10,5%

Reason: In 2024, although some cost items and cost of goods sold increased, the Company recorded income from cargo insurance compensation, helping to offset and increase profit after tax compared to the previous year.

3. Restatement of beginning of the period/ previous period items on 2024 Financial Statements:




In 2024, the Company has adjusted some items in the financial statements for the fiscal year ending 31 December 2023 because they were not properly and fully recorded in the financial statements of previous fiscal years, including the accounting for profits arising from transactions of the Head Office selling goods to branches and the provision for devaluation of inventories. Therefore, some items in the Company's financial statements for the fiscal year ending 31 December 2023 have been adjusted, details as follows:

				Unit: VND
Code	ASSETS	Previously stated	Restated	As Restated
Balance Sheet on 31 December 2023				
141	Inventories	378.956.598.812	156.834.665.736	535.791.264.548
149	Provision for obsolete inventories	(43.158.812.699)	(6.465.276.588)	(49.624.089.287)
313	Statutory obligations	9.722.338.021	44.065.571.343	53.787.909.364
421	Undistributed earnings	139.259.609.169	106.303.817.805	245.563.426.974
421a	Undistributed earnings by the end of prior year	25.320.830.327	119.290.017.388	144.610.847.715
Income Statement for the fiscal year ended 31 December 2023				
11	Revenue from goods sold and services rendered	(1.805.186.497.883)	(10.578.187.377)	(1.815.764.685.260)
20	Gross profit from good sold and services rendered	353.172.656.269	(10.578.187.377)	342.594.468.892
30	Operating profit	145.018.658.994	(10.578.187.377)	134.440.471.617
32	Other expenses	(327.038.145)	(3.230.594.364)	(3.557.632.509)
40	Other profit (loss)	47.357.498	(3.230.594.364)	(3.183.236.866)
50	Accounting profit before tax	145.066.016.492	(13.808.781.741)	131.257.234.751
51	Current corporate income tax expense	(33.006.403.606)	822.582.158	(32.183.821.448)
60	Net profit after tax	115.938.778.839	(12.986.199.583)	102.952.579.256
Cash Flow Statement for the year ended 31 December 2023				
1	Profit before tax	145.066.016.492	(13.808.781.741)	131.257.234.751
3	Provisions	28.751.697.546	6.465.276.588	35.216.974.134
8	Operating profit before changes in working capital	206.269.469.502	(7.343.505.153)	198.925.964.349
10	(Increase)/decrease in inventories	3.079.157.556	4.112.910.789	7.192.068.345
11	Increase/(decrease) in payables (other than interest, corporate income tax)	(173.202.423.533)	3.230.594.364	(169.971.829.169)

Above is the explanation of the Company on fluctuations in Business results of the Company in 2024 compared to 2023 and restatement of beginning of the period/ previous period items on the 2024 Financial Statements.

The restatement of the 2023 Financial Statements and the revision of the 2024 Financial Statements are carried out in a spirit of transparency, honesty, and compliance with applicable accounting standards.



Central Pharmaceutical CPC1.JSC respectfully informs the State Securities Commission and Hanoi Stock Exchange.

Sincerely,

Recipients:

- As above;
- Archives: Clerical, Accounting, Admin.

ACTING GENERAL DIRECTOR



Tạ Văn Dũng

